Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection
Naoya Sakamoto(Chibaken Saiseikai Narashino Hospital), Hiroaki Haga(Yamagata University), Kazumichi Abe(Fukushima Medical University), Naoki Kawagishi(Hokkaido University), Goki Suda(Sapporo University), Masatsugu Ohara(Hokkaido University), Yoshihito Uchida(Saitama Medical University), Hiromasa Ohira(Fukushima Medical University), Chitomi Hasebe(Japanese Red Cross Asahikawa Hospital), Masaru Baba(Hokkaido hospital), Mitsuteru Natsuizaka(Sapporo University), Masato Nakai(Hokkaido University), Katsumi Terasita(Hokkaido hospital), Takuya Sho(Hokkaido University), Atsushi Takahashi(Fukushima Medical University), Satoshi Mochida(Saitama Medical University), Yoshiyuki Ueno(Yamagata Prefectural University of Health Sciences), Namiki Izumi(Musashino Red Cross Hospital), Koji Ogawa(The Japanese Society of Gastroenterological Surgery), Jun Itakura(Musashino Red Cross Hospital), Kenichi Morikawa(Hokkaido University), Masayuki Kurosaki(Musashino Red Cross Hospital), Ken Furuya(Hokkaido hospital), Yoshiya Yamamoto, Masami Abe(University of Oxford), Tomoe Kobayashi(Shigei Medical Research Institute), Yoko Tsukuda(Hokkaido University), Jun Inoue(Tohoku University), Takaaki Izumi(Hokkaido University)
Cited by 27
Related Papers
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
|Cancer Research|2019|328
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272